Related Experiment Video
Updated: May 12, 2026
04:38
Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
Published on: March 28, 2018
Primary biliary cirrhosis: therapeutic advances.
Frank Czul1, Adam Peyton, Cynthia Levy
1Department of Medicine, University of Miami Miller School of Medicine, Room 600D, Central Building, 1611 NW 12th Avenue, Miami, FL 33101, USA.
Clinics in Liver Disease
|April 2, 2013
Summary
Primary biliary cirrhosis (PBC) is a progressive liver disease. Current treatments focus on slowing disease progression and managing symptoms, with ursodeoxycholic acid being the only FDA-approved option.
Area of Science:
- Hepatology
- Immunology
- Gastroenterology
Background:
- Primary biliary cirrhosis (PBC) is a chronic, progressive cholestatic liver disease.
- It is characterized by the destruction of interlobular bile ducts, potentially leading to fibrosis, cirrhosis, and liver failure.
- Liver transplantation is the only definitive cure for PBC.
Purpose of the Study:
- To review current therapeutic advances in the management of Primary Biliary Cirrhosis.
- To discuss the goals of PBC treatment, including slowing disease progression, alleviating symptoms, and preventing complications.
Main Methods:
- This review summarizes existing literature on therapeutic strategies for PBC.
- It focuses on both established treatments and agents currently under evaluation.
Main Results:
- Ursodeoxycholic acid is the sole US FDA-approved medical treatment for PBC.
- Several other agents are being investigated for use as monotherapy or in combination with ursodeoxycholic acid.
Conclusions:
- Current therapeutic strategies aim to manage PBC progression and associated symptoms.
- Ongoing research is exploring novel treatments to improve outcomes for patients with Primary Biliary Cirrhosis.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:17Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:30Acute Pancreatitis II: Clinical Manifestations and Management
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...